Discover how the U.S. castration-resistant prostate cancer (CRPC) market is evolving with advanced targeted therapies, radioligand treatment adoption, and precision oncology approaches improving outcomes for hormone refractory patients. https://www.openpr.com/news/4318357/united-states-hormone-refractory-prostate-cancer-market